pd 153035 and bortezomib

pd 153035 has been researched along with bortezomib in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
An, J; Rettig, MB1

Other Studies

1 other study(ies) available for pd 153035 and bortezomib

ArticleYear
Epidermal growth factor receptor inhibition sensitizes renal cell carcinoma cells to the cytotoxic effects of bortezomib.
    Molecular cancer therapeutics, 2007, Volume: 6, Issue:1

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Renal Cell; Cell Cycle; Cell Death; Cell Survival; Drug Administration Schedule; Drug Synergism; ErbB Receptors; Inhibitory Concentration 50; Kidney Neoplasms; NF-kappa B; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pyrazines; Quinazolines

2007